Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

1.60USD
23 May 2018
Change (% chg)

$-0.01 (-0.93%)
Prev Close
$1.61
Open
$1.61
Day's High
$1.62
Day's Low
$1.59
Volume
180,597
Avg. Vol
1,068,096
52-wk High
$4.83
52-wk Low
$1.42

Chart for

About

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin... (more)

Overall

Beta: 1.31
Market Cap(Mil.): $778.34
Shares Outstanding(Mil.): 224.95
Dividend: --
Yield (%): --

Financials

  SGYP.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -1.16 -- --
ROI: -259.71 1.57 14.38
ROE: -525.34 2.43 16.07

BRIEF-Synergy Pharmaceuticals Reports Q1 Loss Per Share $0.15

* SYNERGY PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

May 10 2018

BRIEF-Synergy Pharmaceuticals Qtrly Loss Per Share ‍$0.16

* SYNERGY PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

Mar 01 2018

BRIEF-Cipher Pharmaceuticals Acquires Exclusive Canadian Rights To FDA-Approved Trulance® From Synergy Pharma

* CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO FDA-APPROVED TRULANCE® FROM SYNERGY PHARMACEUTICALS

Feb 28 2018

BRIEF-Paulson & Co Dissolves Share Stake In Sprint, Cuts In Synergy Pharmaceuticals ‍​

* PAULSON & CO CUTS SHARE STAKE IN SYNERGY PHARMACEUTICALS TO 4 MILLION SHARES FROM 24.1 MILLION SHARES - SEC FILING

Feb 14 2018

BRIEF-Synergy Pharma Meets Cash Balance Requirement

* SYNERGY PHARMACEUTICALS SAYS HAS MET CASH BALANCE REQUIREMENT TO ACCESS ADDITIONAL CAPITAL UNDER TERM LOAN AGREEMENT DATED SEPT 1, 2017 Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Synergy Pharmaceuticals Announces FDA Approval Of TRULANCE

* SYNERGY PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF TRULANCE® (PLECANATIDE) FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN ADULTS

Jan 25 2018

BRIEF-Synergy Pharmaceuticals Appoints Troy Hamilton Chief Executive Officer

* SYNERGY PHARMACEUTICALS APPOINTS TROY HAMILTON CHIEF EXECUTIVE OFFICER

Dec 19 2017

Earnings vs. Estimates